Title
Cost-effectiveness of a decentralised molecular point-of-care testing programme for sexually transmitted infections in remote primary care health services in Australia
Link to article in PubMed
Author(s)
Watts, Caroline
Causer, Louise
Matthews, Susan J
Smith, Kirsty
Andrewartha, Kelly
Tangey, Annie
Hui, Ben B
Huang, Rae-Lin
Anderson, David
Badman, Steven
Donovan, Basil
Fairley, Christopher
Hengel, Belinda
Kaldor, John
Maher, Lisa
Mak, Donna
Persing, David
Regan, David
Shephard, Mark
Speers, David
Wand, Handan
Ward, James
Whiley, David
White, Caitlyn
Wiseman, Virginia
Guy, Rebecca
Abstract
OBJECTIVES: In remote Australian First Nations communities, the burden of curable sexually transmitted infections (STIs) is highest for young women and men aged 16-29 years and for women is associated with two-fold higher rates of hospitalisations for pelvic inflammatory disease (PID) than for non-First Nations women. Following a randomised trial, decentralised community-led molecular point-of-care (POC) testing for STIs has operated in remote primary care across Australia for more than 7 years, improving uptake and timeliness of treatment for chlamydia, gonorrhoea and trichomonas infections. However, cost-effectiveness remains unknown.
METHODS: A decision analytic model was devised to compare costs and outcomes associated with a POC testing programme for chlamydia, gonorrhoea and trichomonas infections in women and men aged 16-29 years seeking care, compared with standard care (laboratory-based testing). The analysis used a government payer perspective and 10-year time horizon. The primary outcome was the cost ($A) per quality-adjusted life year (QALY) gained. Sensitivity analyses examined uncertainty around the results.
RESULTS: Based on a combined testing positivity rate of 36% and 29% for chlamydia, gonorrhoea and trichomonas for women and men, respectively, the POC testing programme, compared with laboratory testing, produced an estimated incremental cost per QALY ratio (ICER) of $A19 714 (95% CIs $A19 608 to $A19 821) over 10 years. Among those with an STI, the POC testing programme was predicted to reduce diagnosed PID by 30% and preterm/low birth weight babies by 17%. Sensitivity analyses indicated that the ICER was most sensitive to the probability of infection and receiving treatment within 2 days, based on a willingness-to-pay threshold of $A50 000.
CONCLUSION: This health economic evaluation indicates that a scaled molecular POC testing programme for the management of STIs in remote primary care settings is cost-effective compared with standard care. Sustained POC testing in this setting is likely to improve reproductive health outcomes.
METHODS: A decision analytic model was devised to compare costs and outcomes associated with a POC testing programme for chlamydia, gonorrhoea and trichomonas infections in women and men aged 16-29 years seeking care, compared with standard care (laboratory-based testing). The analysis used a government payer perspective and 10-year time horizon. The primary outcome was the cost ($A) per quality-adjusted life year (QALY) gained. Sensitivity analyses examined uncertainty around the results.
RESULTS: Based on a combined testing positivity rate of 36% and 29% for chlamydia, gonorrhoea and trichomonas for women and men, respectively, the POC testing programme, compared with laboratory testing, produced an estimated incremental cost per QALY ratio (ICER) of $A19 714 (95% CIs $A19 608 to $A19 821) over 10 years. Among those with an STI, the POC testing programme was predicted to reduce diagnosed PID by 30% and preterm/low birth weight babies by 17%. Sensitivity analyses indicated that the ICER was most sensitive to the probability of infection and receiving treatment within 2 days, based on a willingness-to-pay threshold of $A50 000.
CONCLUSION: This health economic evaluation indicates that a scaled molecular POC testing programme for the management of STIs in remote primary care settings is cost-effective compared with standard care. Sustained POC testing in this setting is likely to improve reproductive health outcomes.
Publication information
Sex Transm Infect . 2026 Jun 29:sextrans-2025-056863. doi: 10.1136/sextrans-2025-056863. Online ahead of print.
File(s)![Thumbnail Image]()
Loading...
Name
Cost-effectiveness of a decentralised molecular point-of-care testing programme for sexually transmitted infections.pdf
Description
Re-used under a Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/
Size
807.75 KB
Format
Adobe PDF
Checksum
(MD5):35501043906ede5f9e4e0ae08ea91cc9
Date Issued
2026-06-29
Type
Journal Article
Journal Title
Sexually transmitted infections
Permanent link to this record
Owning collection
